Herold KC et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. NEJM. Published online June 9, 2019.
Kuhn C, Weiner HL. Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. Immunotherapy. 2016 Jul;8(8):889-906.
Hagopian W et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes. 2013;62(11):3901-3908.
Sherry N et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomized, placebo-controlled trial. Lancet. 2011;378(9790):487-497.
Syage JA et al. Determination of gluten consumption in celiac disease patients on a gluten-free diet. Am J Clin Nutr. 2018;107(2):201-207.
Guandalini S et al. Direct Costs in Patients with Celiac Disease in the USA: A Retrospective Claims Analysis. Dig Dis Sci. 2016;61(10):2823-2830.
Ettersperger J et al. Interleukin-15-Dependent T-Cell-like Innate Intraepithelial Lymphocytes Develop in the Intestine and Transform into Lymphomas in Celiac Disease. Immunity. 2016 Sep 20;45(3):610-625.
Shah S et al. Patient perception of treatment burden is high in celiac disease compared with other common conditions. Am J Gastroenterol. 2014;109(9):1304-1311.
Abadie V, Jabri B. IL-15: a central regulator of celiac disease immunopathology. Immunol Rev. 2014 Jul;260(1):221-234.
Malamut G et al. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. Clin Invest. 2010;120(6):2131-2143.
Genovese MC et al. Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy. J Rheumatol. 2015;42(10):1752-1760.
Franze et al., Interleukin-34 sustains inflammatory pathways in the gut. Clin Sci (Lond). 2015 Aug;129(3):271-280.
von Tresckow B et al. An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Clin Cancer Res. 2015 Apr 15;21(8):1843-1850.
Moore B et al. Tu2027 Treatment with the CSF-1 Receptor kinase (CSF-1R) Inhibitor JNJ40346527 Suppresses Murine Colitis. Gastroenterology. 2014:146(5):S-900-901.
Marshall D et al. Blockade of colony stimulating factor-1 (CSF-1) leads to inhibition of DSS-induced colitis. Inflamm Bowel Dis. 2007;13(2):219-224.
Franks SE et al. Targeting B cells in treatment of autoimmunity. Curr Opin Immunol. 2016 Dec;43:39-45.
Veri MC et al. Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. Arthritis Rheum. 2010;62(7):1933-1943.
Su K et al. Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J Immunol. 2007 Mar 1;178(5):3272-3280.
Dunne JL et al. Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes. Diabetologia. 2019;62(5):744-753.
Hyöty H et al. Developing a vaccine for type 1 diabetes by targeting coxsackievirus B. Expert Rev Vaccines. 2018;17(12):1071-1083.
Sioofy-Khojine AB et al. Coxsackievirus B1 infections are associated with the initiation of insulin-driven autoimmunity that progresses to type 1 diabetes. Diabetologia. 2018;61(5):1193-1202.
Stone VM et al. A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes. Diabetologia. 2018;61(2):476-481.
Laitinen OH et al. Coxsackievirus B1 is associated with induction of beta-cell autoimmunity that portends type 1 diabetes. Diabetes. 2014;63(2):446-455.
Oikarinen S et al. Virus antibody survey in different European populations indicates risk association between coxsackievirus B1 and type 1 diabetes. Diabetes. 2014 Feb;63(2):655-662.
Romero JR. Pediatric group B coxsackievirus infections. Curr Top Microbiol Immunol. 2008; 323:223-329.